HEALTHSTAT NEWS
STAT+: Kailera’s own ‘triple-G’ drug also looks very powerful
The FDA delayed a decision on AstraZeneca's breast cancer drug camizestrant due to advisory concerns over its trial design. Blackstone Life Sciences is investing $1.3 billion in Apogee Therapeutics for Phase 3 development of zumilokibart, a long-acting atopic dermatitis treatment. Kailera's experimental obesity drug, targeting three hormones, showed significant weight loss in a Phase 1 study.
Mentioned
Related Signal
Adjacent reporting
- STAT+: Pharmalittle: We’re reading about an AstraZeneca breast cancer pill, an ADAP deal in Florida, and more
- STAT+: Pharmalittle: We’re reading about a Parkinson’s drug setback, a Merck lung cancer therapy, and more
- New weight-loss drug Retatrutide showing stronger results than current options
- Experimental obesity drug outperforms traditional weight-loss treatments in early research
- STAT+: FDA to reconsider treatment for rare cancer after surprise rejection
- Ozempic-style drugs linked to major slowdown in cancer spread, new study finds